Literature DB >> 3408646

Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.

P G McKenna1, K L O'Neill, W P Abram, B M Hannigan.   

Abstract

Levels of the nucleotide pathway enzyme thymidine kinase (TK) were assayed in the mononuclear leukocytes and serum of 70 female patients with breast cancer and 98 male and 77 female non-cancer hospital patients. The total TK levels in both mononuclear leukocytes and serum from patients with breast cancer were significantly higher than in controls. The serum TK levels showed a significant correlation with cancer stage. No such correlation was observed with mononuclear leukocyte TK levels. Serum TK from 20 patients with breast cancer and 19 control patients was further assayed to ascertain the relative contributions of the thymidine kinase isozymes TK1 and TK2 to total TK levels. The increase in serum TK from breast cancer patients appears to be due to an increase in both TK1 and TK2 levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3408646      PMCID: PMC2246471          DOI: 10.1038/bjc.1988.141

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Thymidine kinase, DNA synthesis and cancer.

Authors:  S Kit
Journal:  Mol Cell Biochem       Date:  1976-06-15       Impact factor: 3.396

2.  Elevated serum and mononuclear leukocyte thymidine kinase activities in patients with cancer.

Authors:  K O'Neill; P Abram; B Hannigan; G McKenna
Journal:  Ir Med J       Date:  1987-09

3.  Expression of thymidine kinase variants is a function of the replicative state of cells.

Authors:  R Adler; B R McAuslan
Journal:  Cell       Date:  1974-06       Impact factor: 41.582

4.  Regulation of thymidine kinase synthesis in human cells.

Authors:  L J Bello
Journal:  Exp Cell Res       Date:  1974-12       Impact factor: 3.905

5.  Submitochondrial localization and characteristics of thymidine kinase molecular forms in parental and kinase-deficient HeLa cells.

Authors:  S Kit; W C Leung
Journal:  Biochem Genet       Date:  1974-03       Impact factor: 1.890

6.  Thymidine kinase in rat tissues during growth and differentiation.

Authors:  R Machovich; O Greengard
Journal:  Biochim Biophys Acta       Date:  1972-12-29

7.  Comparative study of the thymidine kinase and thymidylate kinase activities and of the feedbach inhibition of thymidine kinase in normal and neoplastic human tissue.

Authors:  H L Gordon; T J Bardos; Z F Chmielewicz; J L Ambrus
Journal:  Cancer Res       Date:  1968-10       Impact factor: 12.701

8.  Alteration of the activity and molecular from of thymidine kinase during development and aging in the mouse cerebellum.

Authors:  P C Caron; B R Unsworth
Journal:  Mech Ageing Dev       Date:  1978-09       Impact factor: 5.432

9.  Effect of 5-fluorouracil on the release of thymidine kinase from hepatoma cells in vitro.

Authors:  A Taylor; O W Jones; M A Grishaver
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

10.  Thymidine kinase isoenzymes in human malignant lymphoma.

Authors:  P H Ellims; M B Van der Weyden; G Medley
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

View more
  9 in total

Review 1.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

3.  Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.

Authors:  Costanza Paoletti; William E Barlow; Erin F Cobain; Mattias Bergqvist; Rita S Mehta; Julie R Gralow; Gabriel N Hortobagyi; Kathy S Albain; Lajos Pusztai; Priyanka Sharma; Andrew K Godwin; Alastair M Thompson; Daniel F Hayes; James M Rae
Journal:  Clin Cancer Res       Date:  2021-09-14       Impact factor: 12.531

4.  Comparison of plasma and tissue thymidine kinase activities.

Authors:  R J Calvert; S Satchithanandam
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

5.  Thymidine kinase in breast cancer.

Authors:  J F Robertson; K L O'Neill; M W Thomas; P G McKenna; R W Blamey
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

6.  Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia.

Authors:  Evita G Weagel; Wei Meng; Michelle H Townsend; Edwin J Velazquez; Rachel A Brog; Michael W Boyer; K Scott Weber; Richard A Robison; Kim L O'Neill
Journal:  Onco Targets Ther       Date:  2017-09-06       Impact factor: 4.147

7.  Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Authors:  Martina Bonechi; Francesca Galardi; Chiara Biagioni; Francesca De Luca; Mattias Bergqvist; Magnus Neumüller; Cristina Guarducci; Giulia Boccalini; Stefano Gabellini; Ilenia Migliaccio; Angelo Di Leo; Marta Pestrin; Luca Malorni
Journal:  Oncotarget       Date:  2018-03-27

8.  Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

Authors:  S Rehn; J S Gronowitz; C Källander; C Sundström; B Glimelius
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

9.  Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.

Authors:  K A Selting; R Ringold; B Husbands; P O Pithua
Journal:  J Vet Intern Med       Date:  2016-05-23       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.